Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

FULC
Fulcrum Therapeutics, Inc. Common Stock
stock NASDAQ

Market Open
Aug 5, 2025 12:54:11 PM EDT
6.91USD-0.790%(-0.05)246,483
6.89Bid   6.92Ask   0.03Spread
Pre-market
Aug 4, 2025 8:12:30 AM EDT
6.82USD-2.011%(-0.14)0
After-hours
Aug 4, 2025 4:00:30 PM EDT
6.96USD-0.287%(-0.02)0
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 10, 2022
07:00AM EST  First patient dosed in Phase 1b trial of FTX-6058 in sickle cell disease; Initial data expected in 2Q 2022   GlobeNewswire Inc
Jan 7, 2022
08:00AM EST  Fulcrum Therapeutics Reports Inducement Grants Under   GlobeNewswire Inc
Jan 6, 2022
08:00AM EST  Fulcrum Therapeutics, Inc.(Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that Bryan Stuart, President and Chief Executive Officer, will present at the virtual 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 at 12:00 p.m. ET.   GlobeNewswire Inc
Jan 4, 2022
08:09AM EST  Fulcrum Therapeutics Appoints Esther Rajavelu As Chief Financial Officer   Benzinga
08:00AM EST  Fulcrum Therapeutics Appoints Esther Rajavelu as Chief   GlobeNewswire Inc
Dec 6, 2021
09:41AM EST  Fulcrum therapeutics shares were trading higher after the company announced results from the 20mg and 30mg dose cohorts in healthy adult volunteers in its Phase 1 clinical trial of FTX-6058.   Benzinga
07:03AM EST  Fulcrum Therapeutics Announces Additional HBG mRNA Induction From Higher Dose Cohorts In Phase 1 Healthy Adult Volunteer Trial Of FTX-6058 For Sickle Cell Disease And New Preclinical Mechanism Data   Benzinga
07:00AM EST  Achieved mean 5.6-fold HBG mRNA induction at 20mg and mean 6.2-fold at 30mg after 14 days of once-daily dosing, further supporting potential of FTX-6058 to provide a functional cure   GlobeNewswire Inc
Nov 17, 2021
08:00AM EST  Fulcrum Therapeutics Appoints Sonja L. Banks to its   GlobeNewswire Inc
Nov 5, 2021
12:07PM EDT  Fulcrum Therapeutics Earnings Perspective: Return On Capital Employed   Benzinga
Nov 4, 2021
08:19AM EDT  The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO   Benzinga
07:28AM EDT  Fulcrum Therapeutics Q3 EPS $(0.57) Beats $(0.65) Estimate, Sales $4.93M Beat $2.25M Estimate   Benzinga
07:00AM EDT  On-track to initiate enrollment by year-end in Phase 1b clinical trial of FTX-6058 in people with sickle cell disease   GlobeNewswire Inc
05:00AM EDT  Earnings Scheduled For November 4, 2021   Benzinga
Nov 3, 2021
07:00AM EDT  Fulcrum Therapeutics, Inc.(Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will be participating in the following upcoming investor conferences:   GlobeNewswire Inc
Oct 31, 2021
02:24PM EDT  The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline   Benzinga
Oct 28, 2021
07:00AM EDT  Fulcrum Therapeutics to Host Third Quarter 2021   GlobeNewswire Inc
Oct 1, 2021
07:00AM EDT  Fulcrum Therapeutics Reports Inducement Grant   GlobeNewswire Inc
Sep 22, 2021
12:56PM EDT  Fulcrum Therapeutics's Return On Capital Employed Overview   Benzinga
07:45AM EDT  The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs   Benzinga
Sep 21, 2021
08:20AM EDT  The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data   Benzinga
Sep 20, 2021
07:05AM EDT  Fulcrum Therapeutics Announces Multiple Presentations During The Virtual Congress Of The World Muscle Society   Benzinga
07:00AM EDT  Presentations highlight progress in the development of losmapimod for FSHD   GlobeNewswire Inc
Sep 15, 2021
07:10AM EDT  Cramer Weighs In On Lennar, Alibaba And More   Benzinga
Sep 10, 2021
07:32AM EDT  Fulcrum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)   RTTNews
07:00AM EDT  Fulcrum Therapeutics Reports Inducement Grant   GlobeNewswire Inc
Sep 8, 2021
07:06AM EDT  Fulcrum Therapeutics Appoints Mel Hayes As Chief Commercial Officer   Benzinga
07:00AM EDT  Fulcrum Therapeutics Appoints Mel Hayes as Chief   GlobeNewswire Inc
Sep 2, 2021
08:20AM EDT  The Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab   Benzinga
07:00AM EDT  Fulcrum Therapeutics, Inc.(Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will be participating in the following upcoming investor conferences:   GlobeNewswire Inc
Sep 1, 2021
07:32AM EDT  The Daily Biotech Pulse: Merck Releases Twin Dose Of Positive Tidings, Astellas Voluntarily Pauses Gene Therapy Study, Ascendis Offering   Benzinga
Aug 27, 2021
07:35AM EDT  The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration   Benzinga
Aug 26, 2021
08:09AM EDT  The Daily Biotech Pulse: Early Approval For Ascendis' Pediatric Growth Hormone Deficiency Treatment, Redhill Biopharma Spikes On Positive COVID-19 Drug Data, RenovoRx IPO   Benzinga
Aug 24, 2021
08:09AM EDT  The Daily Biotech Pulse: Cara's Korsuva Greenlighted By FDA, Clinical Trial Disappointments For Novartis, Theravance, Vertex Inks CRISPR Licensing Deal   Benzinga
Aug 18, 2021
06:39AM EDT  10 Biggest Price Target Changes For Tuesday   Benzinga
Aug 17, 2021
06:24AM EDT  HC Wainwright & Co. Maintains Buy on Fulcrum Therapeutics, Raises Price Target to $40   Benzinga
Aug 16, 2021
04:01PM EDT  Fulcrum Therapeutics Announces Closing of Public Offering of   GlobeNewswire Inc
Aug 15, 2021
12:16PM EDT  The Week Ahead In Biotech: Fate Therapeutics Data Readout, RenovoRx IPO In Focus Amid Tapering Earnings News Flow   Benzinga
11:06AM EDT  The Week Ahead In Biotech (Aug. 15-21): Fate Therapeutics Data Readout, RenovoRx IPO In Focus Amid Tapering Earnings News Flow   Benzinga
Aug 13, 2021
05:52AM EDT  SVB Leerink Maintains Outperform on Fulcrum Therapeutics, Raises Price Target to $37   Benzinga
Aug 12, 2021
02:46PM EDT  Mid-Afternoon Market Update: Dow Drops 50 Points; IEC Electronics Shares Spike Higher   Benzinga
09:28AM EDT  Fulcrum Therapeutics-Sponsored Study Titled 'Relative Bioavailability and Food Effect Study of Losmapimod 15 mg Tablets' Posted To Clinical Trials Website   Benzinga
08:09AM EDT  The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma   Benzinga
Aug 11, 2021
10:08AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For August 11, 2021   Benzinga
09:58AM EDT  Fulcrum Therapeutics Option Alert: Aug 20 $25 Calls Sweep (10) near the Ask: 137 @ $3.4 vs 0 OI; Ref=$23.2601   Benzinga
09:03AM EDT  Benzinga Pro's Top 5 Stocks To Watch For Wednesday, Aug. 11, 2021: XLK, ZEV, DYAI, FULC, BLNK   Benzinga
08:14AM EDT  The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering   Benzinga
08:05AM EDT  Credit Suisse Maintains Outperform on Fulcrum Therapeutics, Raises Price Target to $30   Benzinga
06:24AM EDT  Morgan Stanley Upgrades Fulcrum Therapeutics to Overweight, Announces $34 Price Target   Benzinga
Aug 10, 2021
04:25PM EDT  Fulcrum Therapeutics Reports $100M Common Stock Offering   Benzinga
02:31PM EDT  Mid-Afternoon Market Update: 3D Systems Surges On Upbeat Earnings; Katapult Shares Drop   Benzinga
12:09PM EDT  Mid-Day Market Update: Crude Oil Rises Over 3%; comScore Shares Plummet   Benzinga
11:17AM EDT  UPDATE: Stifel On Fulcrum FTX-6058 Data: 'Safety, with the caveat of a short trial, looks favorable that combined with the target engagement data support advancement into patients'   Benzinga
10:17AM EDT  Mid-Morning Market Update: Markets Open Higher; Sysco Tops Q4 Views   Benzinga
09:22AM EDT  Fulcrum Announces Positive Interim Results From Phase 1 Healthy Volunteer Trial Of FTX-6058 For Sickle Cell Disease   RTTNews
07:55AM EDT  The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts   Benzinga
07:08AM EDT  Fulcrum Therapeutics Q2 EPS $(0.60) Beats $(0.62) Estimate, Sales $4.40M Up From $2.00M YoY   Benzinga
07:08AM EDT  Fulcrum Therapeutics Announces Positive Interim Results from Phase 1 Healthy Adult Volunteer Trial of FTX-6058 for Sickle Cell Disease   Benzinga
07:01AM EDT  Reported positive interim results from ongoing Phase 1 trial in healthy adult volunteers with FTX-6058 for sickle cell disease demonstrating proof of mechanism and proof of biology   GlobeNewswire Inc
07:00AM EDT  Fulcrum Therapeutics Announces Positive Interim Results from Phase   GlobeNewswire Inc
04:05AM EDT  Earnings Scheduled For August 10, 2021   Benzinga
Aug 9, 2021
11:07AM EDT  The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight   Benzinga
Aug 4, 2021
07:00AM EDT  Fulcrum Therapeutics to Host Second Quarter 2021 Financial Results   GlobeNewswire Inc
Jul 28, 2021
07:33AM EDT  The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal   Benzinga
Jun 30, 2021
07:29AM EDT  The Daily Biotech Pulse: COVID Disappointments For Altimmune And Angion, Brickell Jumps On Hyperhidrosis Study Updates, 2 IPOs   Benzinga
Jun 24, 2021
10:27AM EDT  Fulcrum Therapeutics Shares See Volume, Hearing Price Target Increased To New Street High At Stifel; $39 Price Target   Benzinga
10:02AM EDT  Fulcrum Therapeutics shares were trading lower after the company reported the primary endpoint in the ReDUX4 trial in people with facioscapulohumeral muscular dystrophy was not met.   Benzinga
08:12AM EDT  The Daily Biotech Pulse: Lilly Spikes On Alzheimer's Drug Regulatory Filing Plan, Applied Genetics, Arcus Issue Data Readouts, Adcom Test Awaits Incyte, Monte Rosa Prices IPO   Benzinga
07:59AM EDT  Fulcrum Therapeutics Inc. (FULC) said Thursday that its phase 2b trial for people with facioscapulohumeral muscular dystrophy or FSHD did not meet its primary endpoint.   RTTNews
07:24AM EDT  Fulcrum Therapeutics Says Phase 2b Trial, ReDUX4, Did Not Meet Primary Endpoint   RTTNews
07:02AM EDT  Fulcrum Therapeutics Announces Results from ReDUX4 Trial with Losmapimod in Facioscapulohumeral Muscular Dystrophy Demonstrating Slowed Disease Progression and Improved Function Did Not Meet Primary Endpoint   Benzinga
07:00AM EDT  Fulcrum Therapeutics Announces Results from ReDUX4 Trial with   GlobeNewswire Inc
Jun 21, 2021
07:00AM EDT  Fulcrum Therapeutics, Inc.(Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced multiple presentations at the 28th Annual FSHD Society International Research Congress (IRC).   GlobeNewswire Inc
May 12, 2021
04:19PM EDT  Fulcrum Therapeutics, Evofem Biosciences Drug Candidates Receive FDA Fast Track Designation   Benzinga
08:08AM EDT  Fulcrum Therapeutics Inc. (FULC) said Wednesday that the U.S. Food and Drug Administration has granted Fast Track designation to losmapimod for the potential treatment of facioscapulohumeral muscular dystrophy or FSHD.   RTTNews
07:21AM EDT  Fulcrum Therapeutics Announces U.S. FDA Grants Fast Track Designation to Losmapimod for the Potential Treatment of Facioscapulohumeral Muscular Dystrophy   Benzinga
07:12AM EDT  Fulcrum Therapeutics Says FDA Grants Fast Track Designation To Losmapimod   RTTNews
07:00AM EDT  Fulcrum Therapeutics, Inc.(Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to losmapimod for the potential treatment of facioscapulohumeral muscular dystrophy (FSHD).   GlobeNewswire Inc
May 7, 2021
07:00AM EDT  Fulcrum Therapeutics, Inc.(Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will present a corporate overview at the BofA Securities 2021 Virtual Health Care Conference on Thursday, May 13, 2021 at 11:00 a.m. ET.   GlobeNewswire Inc
May 6, 2021
07:54AM EDT  Fulcrum Therapeutics Q1 EPS $(0.54) Beats $(0.66) Estimate, Sales $4.79M Beat $1.42M Estimate   Benzinga
07:49AM EDT  The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom   Benzinga
07:01AM EDT  On track to present data from Phase 2b ReDUX4 trial with losmapimod in facioscapulohumeral muscular dystrophy (FSHD) at virtual FSHD International Research Congress in June 2021   GlobeNewswire Inc
07:00AM EDT  Fulcrum Therapeutics Appoints Christopher Morabito, M.D. as Chief   GlobeNewswire Inc
04:17AM EDT  Earnings Scheduled For May 6, 2021   Benzinga
Apr 29, 2021
07:00AM EDT  Fulcrum Therapeutics to Host First Quarter 2021 Financial Results   GlobeNewswire Inc
Apr 9, 2021
01:15PM EDT  Fulcrum Therapeutics Presents Published Structure Of Investigational Small Molecule FTX-6058 At American Chemical Society Spring 2021 Virtual Conference   Benzinga
01:15PM EDT  Fulcrum Therapeutics Presents Published Structure of   GlobeNewswire Inc
Mar 24, 2021
09:29AM EDT  Fulcrum Therapeutics Appoints Judith A. Dunn, Ph.D. as President   GlobeNewswire Inc
Mar 22, 2021
10:43AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For March 22, 2021   Benzinga
06:37AM EDT  Credit Suisse Initiates Coverage On Fulcrum Therapeutics with Outperform Rating, Announces Price Target of $26   Benzinga
Mar 18, 2021
11:31AM EDT  Fulcrum Therapeutics Presents Data For Potential FSHD Biomarker And Clinical Outcome Assessments At 2021 Muscular Dystrophy Association (MDA) Virtual Clinical & Scientific Conference   Benzinga
11:30AM EDT  DemonstratedWhole-Body MRI captures heterogeneity and provides key disease severity and progression information correlated with FSHD clinical endpoints   GlobeNewswire Inc
Mar 8, 2021
10:53AM EST  Morgan Stanley Maintains Equal-Weight on Fulcrum Therapeutics, Raises Price Target to $12   Benzinga
Mar 4, 2021
08:12AM EST  The Daily Biotech Pulse: FDA Nod For Pfizer, Kiniksa Rises On Commercialization Pact With Regeneron, Bio-Techne To Buy Diagnostic Company   Benzinga
07:08AM EST  Fulcrum Therapeutics Q4 EPS $(0.64) Up From $(0.71) YoY, Sales $4.22M Beat $1.31M Estimate   Benzinga
07:08AM EST  Fulcrum Therapeutics Announces CEO Robert J. Gould, Ph.D. To Retire; Bryan E. Stuart Promoted To President And Chief Executive Officer   Benzinga
07:01AM EST  Company on track to present data from Phase 2b ReDUX4 trial with losmapimod in facioscapulohumeral muscular dystrophy (FSHD) in late-2Q 2021   GlobeNewswire Inc
07:00AM EST  Robert J. Gould, Ph.D. announces retirement; will continue to serve as board member and advisor   GlobeNewswire Inc
04:07AM EST  Earnings Scheduled For March 4, 2021   Benzinga
Mar 2, 2021
01:21PM EST  Stifel Initiates Coverage On Fulcrum Therapeutics with Buy Rating, Announces Price Target of $18   Benzinga
Feb 26, 2021
07:00AM EST  Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2020   GlobeNewswire Inc
07:00AM EST  Fulcrum Therapeutics, Inc.(Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced the companys recognition of Rare Disease Day 2021.   GlobeNewswire Inc
Feb 19, 2021
07:00AM EST  Fulcrum Therapeutics, Inc.(Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will participate in the following virtual investor conferences:   GlobeNewswire Inc
Jan 22, 2021
04:00PM EST  Fulcrum Therapeutics Announces Closing of Public Offering of   GlobeNewswire Inc
Jan 19, 2021
11:23PM EST  Fulcrum Therapeutics Prices Public Offering Of 4 Mln Shares At $11/Shr For Total Gross Proceeds Of $44.0 Mln   RTTNews
10:34PM EST  Fulcrum Therapeutics Announces Pricing of Public Offering of   GlobeNewswire Inc
04:02PM EST  Fulcrum Therapeutics Announces Proposed Public Offering of Common Stock; No Terms Disclosed   Benzinga
04:01PM EST  Fulcrum Therapeutics Announces Proposed Public Offering of Common   GlobeNewswire Inc
04:00PM EST  Fulcrum Therapeutics Announces Promotion of Christopher Moxham, Ph   GlobeNewswire Inc
Jan 6, 2021
07:00AM EST  Fulcrum Therapeutics, Inc.(Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will participate in a fireside chat at the virtual H.C. Wainwright BioConnect Conference.   GlobeNewswire Inc
Dec 9, 2020
07:00AM EST  Event will review the companys novel approach to inducing fetal hemoglobin   GlobeNewswire Inc
Dec 5, 2020
10:00AM EST  Fulcrum Therapeutics Presents Updated Data on Sickle Cell Disease   GlobeNewswire Inc
Dec 3, 2020
08:00AM EST  Pandion Therapeutics Appoints Katina Dorton to its Board of Directors   GlobeNewswire Inc
Nov 13, 2020
07:30AM EST  Fulcrum Therapeutics, Inc.(Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will participate in the following virtual investor conferences:   GlobeNewswire Inc
Nov 10, 2020
11:31AM EST  SVB Leerink Maintains Outperform on Fulcrum Therapeutics, Lowers Price Target to $23   Benzinga
08:40AM EST  The Daily Biotech Pulse: Lilly's COVID-19 Antibody Treatment Approved For Emergency Use, Supernus Faces Twin Regulatory Setbacks, Revance, Arena Flunk Midstage Studies   Benzinga
07:00AM EST  ReDUX4 trial progressing; full data withlosmapimod in facioscapulohumeral muscular dystrophy (FSHD) expected in 2Q 2021   GlobeNewswire Inc
Nov 8, 2020
03:58PM EST  The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions   Benzinga
12:47PM EST  The Week Ahead In Biotech: Earnings, Conference Presentations And IPOs   Benzinga
Nov 4, 2020
04:01PM EST  Fulcrum Therapeutics Announces Multiple Presentations During the   GlobeNewswire Inc
Nov 3, 2020
07:00AM EST  Fulcrum Therapeutics to Host Third Quarter 2020 Financial Results   GlobeNewswire Inc
Oct 16, 2020
09:40AM EDT  Benzinga's Top Upgrades, Downgrades For October 16, 2020   Benzinga
05:54AM EDT  Piper Sandler Initiates Coverage On Fulcrum Therapeutics with Overweight Rating, Announces Price Target of $22   Benzinga
Oct 5, 2020
07:11AM EDT  Fulcrum Therapeutics To Initiate Phase 1 Trial With FTX-6058 For Sickle Cell Disease   RTTNews
07:00AM EDT  Fulcrum Therapeutics to Initiate Phase 1 Trial with FTX-6058 for   GlobeNewswire Inc
Oct 1, 2020
07:00AM EDT  Fulcrum Therapeutics, Inc.(Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced it will present multiple posters on the companys ongoing studies in patients with facioscapulohumeral muscular dystrophy (FSHD) during the 25th International Congress of the World Muscle Society.   GlobeNewswire Inc
Sep 25, 2020
02:21PM EDT  Illinois American Water Acquires Granite City Wastewater Collection System   Benzinga
02:16PM EDT  Fulcrum Therapeutics Announces Preclinical Proof-Of-Concept Data For FTX-6058 At Virtual 14th Annual Sickle Cell Disease Research And Educational Symposium, 43rd National Sickle Cell Disease Scientific Meeting   Benzinga
02:15PM EDT  - Fetal Hemoglobin expression in human cellular models increased up to ~30% by FTX-6058 for the potential treatment of sickle-cell disease   GlobeNewswire Inc
Sep 8, 2020
07:00AM EDT  Fulcrum Therapeutics, Inc.(Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will participate in the following virtual investor conferences:   GlobeNewswire Inc
Aug 12, 2020
08:08AM EDT  10 Biggest Price Target Changes For Wednesday   Benzinga
07:41AM EDT  B of A Securities Downgrades Fulcrum Therapeutics to Underperform, Announces $11 Price Target   Benzinga
06:34AM EDT  HC Wainwright & Co. Maintains Buy on Fulcrum Therapeutics, Lowers Price Target to $20   Benzinga
05:29AM EDT  Morgan Stanley Downgrades Fulcrum Therapeutics to Equal-Weight, Lowers Price Target to $11   Benzinga
Aug 11, 2020
02:40PM EDT  Mid-Afternoon Market Update: Dow Rises 1%; Kforce Shares Climb On Upbeat Q2 Results   Benzinga
12:11PM EDT  Mid-Day Market Update: Gold Plunges Over 4%; Pfenex Shares Spike Higher   Benzinga
10:30AM EDT  Mid-Morning Market Update: Markets Mostly Higher; SYSCO Reports Q2 Loss   Benzinga
10:01AM EDT  Morning Market Stats in 5 Minutes   Benzinga
07:18AM EDT  Fulcrum Therapeutics Announces Interim Analysis Data From ReDUX4 Trial In Facioscapulohumeral Muscular Dystrophy   RTTNews
07:03AM EDT  Fulcrum Therapeutics Announces Interim Analysis Data From Its ReDUX4 Trial In Facioscapulohumeral Muscular Dystrophy   Benzinga
07:02AM EDT  Fulcrum Therapeutics Q2 EPS $(0.66) Beats $(0.78) Estimate   Benzinga
07:01AM EDT  Fulcrum Therapeutics Reports Recent Business Highlights and Second   GlobeNewswire Inc
07:00AM EDT  Reduction in DUX4-driven gene expression observed in biopsies with highest baseline levels of DUX4-driven gene expression   GlobeNewswire Inc
04:02AM EDT  Earnings Scheduled For August 11, 2020   Benzinga
Aug 6, 2020
07:00AM EDT  Fulcrum Therapeutics, Inc.(Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will participate in the following virtual investor conferences:   GlobeNewswire Inc
Aug 5, 2020
07:00AM EDT  Fulcrum Therapeutics to Host Second Quarter 2020 Financial Results   GlobeNewswire Inc
Jul 21, 2020
08:02AM EDT  MyoKardia, Fulcrum Therapeutics Enter Strategic Collaboration And License Agreement   RTTNews
07:35AM EDT  MyoKardia and Fulcrum Therapeutics Announce Multi-Target Collaboration To Discover Novel Targeted Therapies For Genetic Cardiomyopathies   Benzinga
07:30AM EDT  MyoKardia and Fulcrum Therapeutics Announce Multi-Target   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC